Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313642142> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4313642142 endingPage "S39" @default.
- W4313642142 startingPage "S38" @default.
- W4313642142 abstract "Objective Assess number needed to treat (NNT) and costs required to achieve improvements in symptoms and functional activities with targeted therapies for myasthenia gravis (MG). Background NNT and cost per improved efficacy can help inform comparative clinical efficacy and cost-effectiveness across MG treatments. Design/Methods Relative to conventional therapy (CT), NNTs and annual costs for achieving one point improvement in Quantitative Myasthenia Gravis score (QMG), one additional patient with minimal clinically important difference (MCID) in QMG (i.e., = 3 points improvement), and one additional patient achieving minimal symptom expression (MSE; Myasthenia Gravis-Activities of Daily Living score of 0 or 1) were estimated for efgartigimod (EFG), intravenous immunoglobulin (IVIg), and eculizumab (ECU). All treatments were used in conjunction with CT. Costs per improved outcome (CPR) were compared between EFG, IVIg, and ECU. Efficacy evaluated at week 4 of respective phase 3 randomized trials (ADAPT [NCT03669588], NCT02473952, REGAIN [NCT01997229]. Annual drug acquisition and administration costs (2021 USD) were considered. Results Compared with CT, mean NNTs to achieve one point improvement and MCID in QMG were 0.19 and 2.03 for EFG, 0.52 and 7.14 for IVIg, and 0.56 and 6.25 for ECU. NNTs to achieve an additional patient with MSE was 3.46 for EFG and 8.13 for ECU. Compared to EFG, the mean annual CPR to achieve one point improvement and MCID in QMG were higher for IVIg (Difference [95% confidence interval] = $36,130 [$14,024, $58,237] per point improvement in QMG; $661,561 [$0, $1,546,275] per one patient with MCID in QMG) and ECU ($340,659 [$158,038, $523,280]; $3,838,718 [$1,470,740, $6,206,695]). Cost to achieve one additional patient with MSE was $4,761,649 [$2,859,671, $6,663,626] higher for ECU compared with EFG. Conclusions Evidence indicates more favorable treatment benefit and economic value for EFG with fewer NNT and lower cost required to achieve improved outcomes compared to other treatments." @default.
- W4313642142 created "2023-01-07" @default.
- W4313642142 creator A5012392332 @default.
- W4313642142 creator A5014513006 @default.
- W4313642142 creator A5015168451 @default.
- W4313642142 creator A5043869405 @default.
- W4313642142 creator A5060914048 @default.
- W4313642142 creator A5061336466 @default.
- W4313642142 creator A5065566858 @default.
- W4313642142 creator A5069811479 @default.
- W4313642142 creator A5091667531 @default.
- W4313642142 date "2022-12-05" @default.
- W4313642142 modified "2023-10-16" @default.
- W4313642142 title "Numbers Needed to Treat and Costs Per Improved Outcome Among Treatments for Myasthenia Gravis" @default.
- W4313642142 doi "https://doi.org/10.1212/01.wnl.0000903312.05490.05" @default.
- W4313642142 hasPublicationYear "2022" @default.
- W4313642142 type Work @default.
- W4313642142 citedByCount "0" @default.
- W4313642142 crossrefType "journal-article" @default.
- W4313642142 hasAuthorship W4313642142A5012392332 @default.
- W4313642142 hasAuthorship W4313642142A5014513006 @default.
- W4313642142 hasAuthorship W4313642142A5015168451 @default.
- W4313642142 hasAuthorship W4313642142A5043869405 @default.
- W4313642142 hasAuthorship W4313642142A5060914048 @default.
- W4313642142 hasAuthorship W4313642142A5061336466 @default.
- W4313642142 hasAuthorship W4313642142A5065566858 @default.
- W4313642142 hasAuthorship W4313642142A5069811479 @default.
- W4313642142 hasAuthorship W4313642142A5091667531 @default.
- W4313642142 hasBestOaLocation W43136421421 @default.
- W4313642142 hasConcept C111278954 @default.
- W4313642142 hasConcept C126322002 @default.
- W4313642142 hasConcept C141341695 @default.
- W4313642142 hasConcept C168563851 @default.
- W4313642142 hasConcept C1862650 @default.
- W4313642142 hasConcept C203092338 @default.
- W4313642142 hasConcept C2778105408 @default.
- W4313642142 hasConcept C44249647 @default.
- W4313642142 hasConcept C67774102 @default.
- W4313642142 hasConcept C71924100 @default.
- W4313642142 hasConcept C82789193 @default.
- W4313642142 hasConceptScore W4313642142C111278954 @default.
- W4313642142 hasConceptScore W4313642142C126322002 @default.
- W4313642142 hasConceptScore W4313642142C141341695 @default.
- W4313642142 hasConceptScore W4313642142C168563851 @default.
- W4313642142 hasConceptScore W4313642142C1862650 @default.
- W4313642142 hasConceptScore W4313642142C203092338 @default.
- W4313642142 hasConceptScore W4313642142C2778105408 @default.
- W4313642142 hasConceptScore W4313642142C44249647 @default.
- W4313642142 hasConceptScore W4313642142C67774102 @default.
- W4313642142 hasConceptScore W4313642142C71924100 @default.
- W4313642142 hasConceptScore W4313642142C82789193 @default.
- W4313642142 hasIssue "23" @default.
- W4313642142 hasLocation W43136421421 @default.
- W4313642142 hasOpenAccess W4313642142 @default.
- W4313642142 hasPrimaryLocation W43136421421 @default.
- W4313642142 hasRelatedWork W1497600279 @default.
- W4313642142 hasRelatedWork W1997896518 @default.
- W4313642142 hasRelatedWork W2089903975 @default.
- W4313642142 hasRelatedWork W2108647028 @default.
- W4313642142 hasRelatedWork W2324954285 @default.
- W4313642142 hasRelatedWork W2959603226 @default.
- W4313642142 hasRelatedWork W3138366407 @default.
- W4313642142 hasRelatedWork W3173946236 @default.
- W4313642142 hasRelatedWork W4377564586 @default.
- W4313642142 hasRelatedWork W4384342251 @default.
- W4313642142 hasVolume "99" @default.
- W4313642142 isParatext "false" @default.
- W4313642142 isRetracted "false" @default.
- W4313642142 workType "article" @default.